» Articles » PMID: 35201850

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer

Abstract

Purpose: The study of plasma cell-free DNA integrity (cfDI) has shown potential for providing useful information in neoplastic patients. The aim of this study is to estimate the accuracy of an electrophoresis-based method for cfDI evaluation in the assessment of pathologic complete response (pCR) in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT).

Patients And Methods: Fifty-one patients with BC undergoing anthracycline-/taxane-based NACT were recruited. Plasma samples were collected from each patient at diagnosis (t0), after anthracycline administration (t1), and after NACT completion (t2). The concentration of differently sized cell-free DNA fragments was assessed by automated electrophoresis. cfDI, expressed as cfDI index, was calculated as the ratio of 321-1,000 bp sized fragment concentration to 150-220 bp sized fragment concentration assessed at t2. cfDI index was then used to build an exploratory classifier for BC response to NACT, directly comparing its sensitivity and specificity with magnetic resonance imaging (MRI), through bootstrapped logistic regression.

Results: cfDI index was assessed on 38 plasma samples collected from as many patients at t2, maintaining a 30/70 ratio between pCR and non-pCR patients. cfDI index showed an area under the receiver operating characteristic curve in predicting the achievement of pCR of 81.6, with a cutoff above 2.71 showing sensitivity = 81.8 and specificity = 81.5. The combination of cfDI index and MRI showed, in case of concordance, an area under the receiver operating characteristic curve of 92.6 with a predictive value of complete response of 87.5 and a predictive value of absence of complete response of 94.7.

Conclusion: cfDI index measured after NACT completion shows great potential in the assessment of pCR in patients with BC. The evaluation of its use in combination with MRI is strongly warranted in prospective studies.

Citing Articles

Circulating Cell-Free DNA Integrity for Breast and Prostate Cancer: What Is the Landscape for Clinical Management of the Most Common Cancers in Women and Men?.

Sobhani N, Tierno D, Pavan N, Generali D, Grassi G, Zanconati F Int J Mol Sci. 2025; 26(3).

PMID: 39940669 PMC: 11817310. DOI: 10.3390/ijms26030900.


Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study.

Giro C, Yamada A, Cruz F, do R Barros L, da C A Alves B, Fonseca F Breast Cancer Res Treat. 2024; 206(2):329-335.

PMID: 38743176 DOI: 10.1007/s10549-024-07366-y.

References
1.
El Tarhouny S, Seefeld M, Fan A, Hahn S, Holzgreve W, Zhong X . Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine. 2008; 44(1):65-9. DOI: 10.1016/j.cyto.2008.06.008. View

2.
Pathak M, Dwivedi S, Deo S, Thakur B, Sreenivas V, Rath G . Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev. 2018; 7(1):89. PMC: 6020442. DOI: 10.1186/s13643-018-0754-1. View

3.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

4.
Mouliere F, Chandrananda D, Piskorz A, Moore E, Morris J, Ahlborn L . Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018; 10(466). PMC: 6483061. DOI: 10.1126/scitranslmed.aat4921. View

5.
Sener S, Sargent R, Lee C, Manchandia T, Le-Tran V, Olimpiadi Y . MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2019; 120(6):903-910. PMC: 7433761. DOI: 10.1002/jso.25663. View